Skip to content
OpenCapital
Get started

Inovio Pharmaceuticals INO Q1 2026 earnings

Reported May 13, 2026 · After market close

Diluted EPS-$0.28Beat by $0.02
Revenue estimate$333.3K
EPS estimate-$0.30

Next report

Aug 12, 2026 (in a month)
Revenue estimate$533.3K
EPS estimate-$0.28

Versus estimates

Revenue

Q1 2025$65.3KBeat by $55.3KQ4 2024$117.0KBeat by $67.0K

Diluted EPS

Q1 2026-$0.28Beat by $0.02
Q4 2025$0.31Beat by $0.68Q3 2025-$0.44Beat by $0.07Q2 2025-$0.61Beat by $0.02Q1 2025-$0.51Beat by $0.23Q4 2024-$0.69Beat by $0.18

Ask the moment Inovio Pharmaceuticals reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Inovio Pharmaceuticals report Q1 2026 earnings?
Inovio Pharmaceuticals (INO) reported Q1 2026 earnings on May 13, 2026 after market close.
What were Inovio Pharmaceuticals's Q1 2026 revenue and EPS?
Inovio Pharmaceuticals reported diluted EPS of $-0.28 for Q1 2026.
Did Inovio Pharmaceuticals beat estimates in Q1 2026?
EPS beat the consensus estimate of $-0.30 by $0.02.
How did Inovio Pharmaceuticals's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, diluted EPS grew 45.1% from $-0.51.
Where can I find Inovio Pharmaceuticals's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001055726-26-000019) and the 10-Q periodic report (0001055726-26-000018) directly on SEC EDGAR. The filing index links above go to sec.gov.